BioCryst’s Price Target Raised to $22 as Q4 EPS Hits $1.12 on $406.5M Revenue
Wedbush raised BioCryst's price target to $22 from $21, maintained its Outperform rating and left FY26 guidance and peak revenue forecasts unchanged after closing the Astria acquisition. BioCryst posted Q4 EPS of $1.12 on $406.5m revenue versus a $0.13 loss on $131.5m year-ago sales.
1. Price Target Raise and Outlook
Wedbush increased BioCryst’s price target to $22 from $21 and kept its Outperform rating following the Astria Therapeutics acquisition. The firm cited smooth commercial operations and management’s decision to uphold FY26 revenue guidance and peak revenue targets as key factors.
2. Q4 Financial Performance
In Q4, BioCryst reported EPS of $1.12 versus a $0.13 loss a year earlier and generated $406.5 million in revenue, up from $131.5 million. This surge was driven by the highest level of new Orladeyo prescriptions since its initial launch and marked the company’s first full-year profitability.
3. Astria Therapeutics Acquisition
The completion of the Astria acquisition expanded BioCryst’s hereditary angioedema portfolio and is expected to enhance long-term growth. Management highlighted the deal’s role in broadening patient access and strengthening its leadership position in HAE treatment.
4. Pipeline Advances and Future Catalysts
BioCryst anticipates additional clinical data from BCX17725 by the end of 2026 to support its rare disease pipeline. Ongoing collaborations with major pharmaceutical partners aim to advance multiple candidates through late-stage trials.